

Journal Pre-proof

Network Meta-Analysis of Ulcerative Colitis Pharmacotherapies: Carryover Effects from Induction and Bias of the Results

Dominik Naessens, Chris Cameron, David C. Hoaglin



PII: S1542-3565(20)31428-2
DOI: <https://doi.org/10.1016/j.cgh.2020.10.016>
Reference: YJCGH 57554

To appear in: *Clinical Gastroenterology and Hepatology*
Accepted Date: 8 October 2020

Please cite this article as: Naessens D, Cameron C, Hoaglin DC, Network Meta-Analysis of Ulcerative Colitis Pharmacotherapies: Carryover Effects from Induction and Bias of the Results, *Clinical Gastroenterology and Hepatology* (2020), doi: <https://doi.org/10.1016/j.cgh.2020.10.016>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 by the AGA Institute

Title: Network Meta-Analysis of Ulcerative Colitis Pharmacotherapies: Carryover Effects from Induction and Bias of the Results

Authors: Dominik Naessens, Janssen Pharmaceutica NV, Beerse, Belgium

Chris Cameron, EVERSANA, Burlington, Ontario, Canada

David C. Hoaglin, University of Massachusetts Medical School, Worcester, MA, United States

Corresponding Author: Dominik Naessens

Disclosures: Dominik Naessens is a Janssen employee and owns Johnson & Johnson stock and stock options. Chris Cameron and David Hoaglin have received consulting fees from Janssen.

Word count: 720 words

Word limit: 750 words

Dear Editor,

In their network meta-analyses (NMAs) of treatments for ulcerative colitis (UC), Singh et al¹ did not take into account a complication associated with studies that re-randomized patients for the maintenance phase: differential carryover effects from induction can bias the results. In those studies, patients who responded to induction were re-randomized to maintenance treatments that included placebo. If, however, carryover effects from induction differ substantially among active treatments, the effects of those treatments, relative to placebo, are not comparable.

Placebo rates in the re-randomized maintenance studies suggest that ustekinumab provided greater carryover effects from induction than the other treatments. In the biologic-non-failure populations, 31.0% in the ustekinumab study,² 20.5% in the vedolizumab study,³ 15.6% in the golimumab study,⁴ and 11.0% in the tofacitinib study⁵ were in clinical remission after

responding to induction and receiving placebo maintenance (Chi-squared test, $p < 0.001$). In the biologic-failure populations, 17.0% in the ustekinumab study, 11.2% in the tofacitinib study, and 5.3% in the vedolizumab study were in clinical remission ($p < 0.001$, not evaluated in the golimumab study). This trend was previously observed in randomized-withdrawal studies in patients with Crohn's disease,⁶ suggesting that it is a characteristic of ustekinumab induction treatment and not related to a unique aspect of the UC study population.

Because of these differences in carryover effects, the "placebo" groups in the re-randomized maintenance studies cannot serve as a common comparator. They are not true placebo groups, because they consist of patients who responded to different induction treatments and were evaluated after receiving placebo maintenance. Thus, the NMA of re-randomized maintenance studies underestimated the incremental benefit that ustekinumab maintenance provided over placebo and therefore relative to other treatments. The difference between ustekinumab and placebo maintenance did not reach statistical significance in the NMA (odds ratio [95% confidence interval] 2.46 [0.61,9.88] for clinical remission and 2.62 [0.95,7.23] for endoscopic improvement], eTable 2B). These estimates directly contradict the actual results from the UNIFI study, in which differences between ustekinumab and placebo maintenance were both statistically significant and clinically meaningful.² The failure to corroborate the original results from this large, prospective, randomized, pivotal study underscores the flawed methodology of this NMA.

Overall, the NMA of re-randomized maintenance studies was based on a thin network of 6 trials and 4 UC treatments versus placebo, and the results indicate that the network contained substantial heterogeneity. For each direct comparison of clinical remission in the pairwise meta-analysis (MA) (Supplemental Figure 5A), the corresponding odds ratio in the NMA has a much wider confidence interval (eTable 2B). One would expect the NMA not to have such wide confidence intervals, since it can draw from the whole network to estimate the heterogeneity variance. However, the comparison between the pairwise MA and the NMA is difficult to interpret because the pairwise MA used the Mantel-Haenszel fixed-effect method, and the assumptions used in the software to estimate the heterogeneity variance in the NMA were not reported. Comparisons with results from the DerSimonian-Laird random-effects method would

have been more informative, along with a detailed description of the NMA methods and publication of the code used in the analysis.

Heterogeneity in randomized-withdrawal trial designs can be accounted for by recalculating data to mimic a treat-through design, maintaining the initial randomized treatment groups from induction, accounting for initial and delayed responders to induction treatment, and using true placebo as a common comparator. Welty et al⁷ used this approach in an NMA of UC studies and found that ustekinumab had greater probabilities of clinical response, clinical remission, and endoscopic improvement through 1 year in patients who had not failed biologics than adalimumab, vedolizumab, golimumab, and infliximab. This approach allowed use of a larger network that consisted of studies with treat-through designs as well as studies with randomized-withdrawal designs. Notably, even when VARSITY data⁸ were excluded from that NMA, the comparison of vedolizumab versus adalimumab showed a similar direction to VARSITY, further supporting the validity of the NMA methodology.

The underlying assumptions in the NMAs of Singh et al have important implications for treatment of patients with ulcerative colitis. The results were used to formulate the recently published practice guidelines from the American Gastroenterology Association.⁹ Payors may use them to inform formulary decisions that limit patients' access. NMAs are valuable in the absence of direct comparisons of treatments in head-to-head trials, but assumptions implicit in their design must be rigorously scrutinized.

REFERENCES

1. Singh S et al. Clin Gastroenterol Hepatol 2020;18:2179-2191.
2. Sands BE et al. N Engl J Med 2019;381:1201-1214.
3. Feagan BG et al. Clin Gastroenterol Hepatol 2017;15:229-239.e5.
4. Gibson PR et al. Clin Transl Gastroenterol 2016;7:e168.
5. Dubinsky MC et al. World Congress of Gastroenterology at ACG2017 Meeting 2017;Program No. P449.
6. Varu A et al. Curr Med Res Opin 2019;35:733-756.
7. Welty M et al. Curr Med Res Opin 2020;36:595-606.
8. Sands BE et al. N Engl J Med 2019;381:1215-1226.
9. Feuerstein JD et al. Gastroenterology 2020;158:1450-1461.